Elsevier

Atherosclerosis

Volume 101, Issue 1, June 1993, Pages 117-125
Atherosclerosis

Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase

https://doi.org/10.1016/0021-9150(93)90107-6Get rights and content

Abstract

The role of mevalonate and its products (isoprenoids) in the control of cellular proliferation was examined by investigating the effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (vastatins) on growth and on cholesterol biosynthesis of cultured arterial myocytes (SMC). Simvastatin (S) and fluvastatin (F), but not pravastatin (P), decreased the rate of growth of rat vascular SMC. The inhibition, evaluated as cell number, was dose-dependent with IC50 values of 2.8 and 2.2 μM for S and F, respectively; P (1–500 μM) was inactive. The inhibition of cell growth induced by 3.5 μM S (70% decrease) was prevented completely by the addition of 100 μM mevalonate, partially (70–85%) by the addition of 10 μM geraniol, 10 μM farnesol and 5 μM geranylgeraniol, but not by the addition of squalene, confirming the specific role of isoprenoid metabolites in regulating cell proliferation. All the tested vastatins inhibited the incorporation of [14C]acetate into cholesterol but P had 800 times lower potency than S and F. Similar results were obtained in SMC from human femoral artery. At least 80% inhibition of cholesterol synthesis was necessary to induce a decrease in SMC proliferation. To further investigate the relationship between cholesterol synthesis and cell growth, two enantiomers of F were investigated. The enantiomer more active on HMG-CoA reductase was 70- and 1.6-fold more potent on arterial myocyte proliferation than its antipode and the racemic mixture, respectively. A similar IC50 proliferation/cholesterol synthesis ratio for all the inhibitory vastatins (S, F and its enantiomers), regardless of their different potency, supports a causal relationship between the mevalonate synthetic pathway and cell proliferation.

References (52)

  • O.H. Lowry et al.

    Protein measurement with the Folin phenol reagent

    J. Biol. Chem.

    (1951)
  • R.A. Parker et al.

    Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors

    J. Lipid Res.

    (1990)
  • J.A. Glomset et al.

    Prenyl proteins in eukaryotic cells: a new type of membrane anchor

    Trends Biochem. Sci.

    (1990)
  • P.J. Casey

    Biochemistry of protein prenylation

    J. Lipid Res.

    (1992)
  • R.A. Schmidt et al.

    Evidence for post-translational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins

    J. Biol. Chem.

    (1984)
  • J.F. Hancock et al.

    All ras proteins are polyisoprenylated but only some are palmitoylated

    Cell

    (1989)
  • E.M. Repko et al.

    Post-translational isoprenylation of cellular proteins is altered in response to mevalonate availability

    J. Biol. Chem.

    (1989)
  • M. Sinensky et al.

    Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis

    J. Biol. Chem.

    (1990)
  • C.C. Farnsworth et al.

    Human lamin B contains a farnesylated cysteine residue

    J. Biol. Chem.

    (1989)
  • J.H. Ip et al.

    Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation

    J. Am. Coll. Cardiol.

    (1990)
  • R. Sahni et al.

    Prevention of restenosis by lovastatin after succesful coronary angioplasty

    Am. Heart J.

    (1991)
  • R. Ross

    The pathogenesis of atherosclerosis. An update

    N. Engl. J. Med.

    (1986)
  • R.W. Wissler

    Update on the pathogenesis of atherosclerosis

    Am. J. Med.

    (1991)
  • J.L. Goldstein et al.

    Regulation of mevalonate pathway

    Nature

    (1990)
  • W.A. Maltese

    Posttranslational modification of proteins by isoprenoids in mammalian cells

    FASEB J.

    (1990)
  • J.W. Doyle et al.

    Requirement for mevalonate in cycling cells: quantitative and temporal aspects

    J. Cell. Physiol.

    (1988)
  • Cited by (0)

    View full text